Feline Kidney Function Evaluation via Serum Ghrelin Biomarker
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating kidney function in felines are inadequate, as kidney disease often progresses undetected until 60% to 75% of renal mass is lost, necessitating a new approach for early diagnosis and management.
Innovation Solution
Determining serum ghrelin levels in felines and directly correlating them with kidney function, using a method that involves comparing observed ghrelin levels to reference levels to diagnose kidney disease, detect its onset, and assess the efficacy of management regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional kidney function evaluation methods are used, then diagnosis is only possible after significant renal mass loss, but early detection capability is poor
Solution Approach 1:
The patent applies preliminary action by using ghrelin level measurement to detect kidney disease at its onset, before significant renal mass loss occurs. The method enables early diagnosis by measuring ghrelin levels in blood samples, allowing intervention before 60-75% of renal mass is lost, thus preventing the time loss associated with conventional late-stage detection methods.
2Measurement precision
If ghrelin level determination is implemented, then early kidney disease detection is enabled, but measurement complexity increases
Solution Approach 1:
The patent uses ghrelin as an intermediary biomarker to indirectly assess kidney function. Instead of directly measuring complex renal parameters, the method measures ghrelin levels in blood samples, which serve as a mediator that correlates with kidney function status. This approach simplifies the measurement system while maintaining high detection accuracy for early kidney disease.
3Reliability
If conventional monitoring methods are used, then disease progression is detected only at advanced stages, but frequent monitoring increases cost and complexity
Solution Approach 1:
The patent implements feedback by establishing baseline ghrelin levels in healthy felines and comparing subsequent measurements against this baseline. This feedback mechanism allows reliable detection of kidney disease progression by identifying deviations from normal ghrelin levels, enabling continuous monitoring without requiring complex advanced imaging or invasive procedures at each stage.
Data Source
AI summary
Methods for (1) evaluating feline kidney function by determining ghrelin level in feline tissue or biofluid and correlating the ghrelin level directly to kidney function and (2) diagnosing kidney disease in a feline comprises determining an observed ghrelin level in a tissue or biofluid of the feline and comparing the observed ghrelin level to a reference ghrelin level indicative of normal kidney function, wherein an observed level lower than the reference level is indicative of kidney disease or susceptibility thereto.